Skip to content
Clinical Trials – home
Therapeutic area

Musculoskeletal and connective tissue disorders – page 17

  • 865 clinical trials
  • 357 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Clinical trials in Musculoskeletal and connective tissue disorders

865 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

865 clinical trials

Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings SA

Osteoarthritis

Recruiting

Study of Autologous Microfat and Platelet-Rich Plasma Injection Compared to Wrist Denervation in Patients with Radiocarpal Osteoarthritis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Microfat
  • Sponsor:Centre Hospitalier Regional De Marseille

Long-Term Safety and Efficacy Study of Givinostat for Patients with Duchenne Muscular Dystrophy Previously Treated with Givinostat

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Back pain

Recruiting

Study on the Use of Platelet Concentrate and Betamethasone for Treating Chronic Low Back Pain in Patients with Lumbar Disc Degeneration

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Platelet Concentrate
  • Sponsor:Biotechnology Institute I Mas D S.L.

Study on Long-Term Use of Infigratinib for Children with Achondroplasia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Dermatomyositis

Recruiting

Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Periarthritis

Recruiting

Study on Pain Relief for Frozen Shoulder Using Methylprednisolone Acetate and Ropivacaine Hydrochloride in Adults

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine Hydrochloride Monohydrate
  • Sponsor:UZ Brussel

Study on Baricitinib for Patients with Calcium Pyrophosphate Deposition Disease (CPPD) Using Methotrexate Sodium and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Ospedale Galeazzi S.p.A.

Study on the Safety and Effectiveness of CABA-201, Fludarabine Phosphate, and Cyclophosphamide in Patients with Active Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Caba-201
  • Sponsor:Cabaletta Bio Inc.

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study on the Safety and Effects of SPK-3006 for Adults with Late-Onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vanglusagene Ensiparvovec
  • Sponsor:Genentech Inc.

Study on Adjusting Adalimumab Dosage for Patients with Rheumatoid Arthritis in Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.